Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Solid Biosciences Inc.    SLDB

SOLID BIOSCIENCES INC.

(SLDB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SOLID BIOSCIENCES INC. : Other Events (form 8-K)

10/01/2020 | 07:40am EST

Item 8.01 Other Events.

On October 1, 2020, Solid Biosciences Inc. (the "Company") announced that the U.S. Food and Drug Administration (the "FDA") lifted the clinical hold placed on the Company's IGNITE DMD Phase I/II clinical trial. As previously announced in July 2020, the FDA had requested further manufacturing information, updated safety and efficacy data for all patients dosed, and provided direction on total viral load to be administered per patient. Based on the Company's response to these requests, the FDA acknowledged that the Company satisfactorily addressed all clinical hold questions.

In connection with the lifting of the clinical hold, the Company is reducing the maximum weight of the next two patients dosed in IGNITE DMD to 18 kg per patient, with safety outcomes from these two patients driving potential weight increase of patients dosed subsequently. This reduction, in conjunction with the delivery of fewer viral particles as a result of the Company's manufacturing process improvements, will reduce patients' total viral load while continuing dosing at the 2E14 vg/kg dose. Additionally, to mitigate the risk of serious drug-related adverse events, the Company is amending the IGNITE DMD clinical protocol to include the prophylactic use of both anti-complement inhibitor eculizumab and C1 esterase inhibitor, and increasing the prednisone dose in the first month post dosing.

The Company is currently working to complete all activities necessary to resume dosing, which it expects to occur in the first quarter of 2021.

Forward-Looking Statements

This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing and ability of the Company to resume dosing and move the IGNITE DMD clinical trial forward, the safety or potential efficacy of SGT-001 and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," "working" and similar expressions. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's ability to resume and/or continue IGNITE DMD on the timeline expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; obtain and maintain the necessary approvals from investigational review boards at IGNITE DMD clinical trial sites and the IGNITE DMD data safety monitoring board; enroll patients in IGNITE DMD; continue to advance SGT-001 in clinical trials; replicate in clinical trials positive results found in preclinical studies and earlier stages of clinical development; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; successfully optimize and scale its manufacturing process; obtain, maintain or protect intellectual property rights related to its product candidates; compete successfully with other companies that are seeking to develop DMD/Duchenne treatments and gene therapies; manage expenses; and raise the substantial additional capital needed, on the timeline necessary, to resume dosing in the IGNITE DMD trial, continue development of SGT-001, achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about SOLID BIOSCIENCES INC.
01/11SOLID BIOSCIENCES INC. : Regulation FD Disclosure (form 8-K)
AQ
01/08Sarepta's Mixed Results in Duchenne Muscular Dystrophy Trial Could be Good Ne..
MT
01/08SOLID BIOSCIENCES : Credit Suisse Upgrades Solid Biosciences to Neutral from Und..
MT
01/06Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference
GL
2020INSIDER TRENDS : Solid Biosciences Insider Gets Stock Award, Prolongs Buy Trend
MT
2020INSIDER TRENDS : Solid Biosciences Insider Granted Stock Award, Extends Buy Tren..
MT
2020INSIDER TRENDS : Solid Biosciences Insider Receives Stock Award, Trend of Buys E..
MT
2020INSIDER TRENDS : Solid Biosciences Insider Gets Stock Award, Prolongs Buy Trend
MT
2020INSIDER TRENDS : Solid Biosciences Insider Gets Stock Award Retains Shares, Inte..
MT
2020MIDDAY REPORT : Wall Street Weaker Midday On Stimulus Woes
MT
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -87,8 M - -
Net cash 2020 60,6 M - -
P/E ratio 2020 -3,82x
Yield 2020 -
Capitalization 414 M 414 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 121
Free-Float 49,8%
Chart SOLID BIOSCIENCES INC.
Duration : Period :
Solid Biosciences Inc. Technical Analysis Chart | SLDB | US83422E1055 | MarketScreener
Technical analysis trends SOLID BIOSCIENCES INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 6,70 $
Last Close Price 6,28 $
Spread / Highest target 99,0%
Spread / Average Target 6,69%
Spread / Lowest Target -68,2%
EPS Revisions
Managers and Directors
NameTitle
Ilan Ganot President, Chief Executive Officer & Director
Ian Frederick Smith Chairman
Jennifer Ziolkowski Chief Financial Officer & Treasurer
Carl Morris Chief Scientific Officer
Joel Schneider Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
SOLID BIOSCIENCES INC.-17.15%414
GILEAD SCIENCES, INC.12.39%82 081
WUXI APPTEC CO., LTD.36.65%63 102
VERTEX PHARMACEUTICALS-4.69%58 574
REGENERON PHARMACEUTICALS6.72%54 415
BEIGENE, LTD.24.12%29 244